Log In   |   Sign up

New User Registration

Article / Abstract Submission
Register here
Register
Press Release Submission
Register here
Register
coolingZONE Supplier
Register here
Register

Existing User


            Forgot your password
September 2016

BioLife Solutions' CryoStor Integrated in Kolon Group's Osteoarthritis Project


biolife solutions, inc. (nasdaq: blfs), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a relatedcloud hosted biologistics cold chain management app for smart shippers ("biolife" or the "company"), recently announced that its clinical grade cryostor freeze media has been incorporated into the manufacturing process for invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by kolon life science.

 

the kolon group subsidiary filed as of july 8 a biologics license application (bla) for invossa with the korean ministry of food and drug safety. according to kolon, invossa is the world's first cell-mediated gene therapy for osteoarthritis, a degenerative joint disease affecting more than 150 million people.

 

the product was developed by us-based tissuegene, inc. as "tissuegene-c" and is administered via intra-articular injection without the need for anesthesia or surgical intervention. the therapy has demonstrated effectiveness in providing pain and symptomatic relief as well as in delaying the disease's structural progression.

 

mike rice, biolife president & ceo, remarked, "kolon's bla submission seeking approval to market invossa in korea is encouraging news for millions of patients suffering from osteoarthritis.  we are very pleased that tissuegene and kolon have selected cryostor as the best in class biopreservation media for commercializing invossa.

 

“cryostor and hypothermosol®, our cell and tissue storage and shipping media, are now incorporated into more than 220 pre-clinical validations and clinical trials of cell-based therapies, targeting blood cancers, solid tumors, vision loss, heart disease, stroke, and movement disorders such as osteoarthritis.

 

“we look forward to progress by kolon and other customers in gaining regulatory approvals to commence commercial manufacturing of these life-changing and life-saving cell therapies."

Choose category and click GO to search for thermal solutions

 
 

Subscribe to Qpedia

a subscription to qpedia monthly thermal magazine from the media partner advanced thermal solutions, inc. (ats)  will give you the most comprehensive and up-to-date source of information about the thermal management of electronics

subscribe

Submit Article

if you have a technical article, and would like it to be published on coolingzone
please send your article in word format to [email protected] or upload it here

Subscribe to coolingZONE

Submit Press Release

if you have a press release and would like it to be published on coolingzone please upload your pr  here

Member Login

Supplier's Directory

Search coolingZONE's Supplier Directory
GO
become a coolingzone supplier

list your company in the coolingzone supplier directory

suppliers log in

Media Partner, Qpedia

qpedia_158_120






Heat Transfer Calculators